Sivasothy P, Smith I E, Shneerson J M
Respiratory Support and Sleep Centre, Papworth Hospital, Papworth Everard, Cambridge, UK.
Eur Respir J. 1998 Jan;11(1):34-40. doi: 10.1183/09031936.98.11010034.
Noninvasive ventilation in chronic obstructive pulmonary disease (COPD) has been shown to improve arterial blood gases but its long-term role has not been established. We retrospectively studied 26 consecutive patients with hypercapnic ventilatory failure due to COPD in whom oxygen therapy caused worsening hypercapnia (defined as a rise in the daytime arterial carbon dioxide tension (Pa,CO2) to >8.0 kPa or nocturnal transcutaneous carbon dioxide tension (Ptc,CO2) to >9 kPa). All were treated with mask ventilation (15 with nasal and 11 face masks) at night and during daytime naps. Additional oxygen therapy was required in 15 patients. The mean annualized death rate was 10.8% with a 1 and 3 yr survival of 92 and 68%, respectively. After 1 yr the median daytime Pa,CO2 had fallen by 1.35 kPa and the arterial oxygen tension (Pa,O2) had risen by 2.4 kPa. In subjects not using additional oxygen the median overnight Sa,O2 rose by 12% and the Ptc,CO2 fell by 2.8 kPa after 1 yr. The haematocrit was significantly less than pretreatment at 6 months and 1 yr. Quality of life in the domain of role limitation by physical health (measured using the SF-36 questionnaire) improved significantly at 6 months. Survival in this selected group with clinically stable airflow obstruction unable to tolerate oxygen therapy and treated with noninvasive mask ventilation is better than historical controls and is comparable to those able to tolerate oxygen therapy. Poor survival was associated with a low forced expiratory volume in one second, a low body mass index and a high nocturnal transcutaneous carbon dioxide tension. No difference in survival was found between those treated with mask intermittent positive pressure ventilation alone or with mask intermittent positive pressure and supplementary oxygen therapy.
慢性阻塞性肺疾病(COPD)的无创通气已被证明可改善动脉血气,但它的长期作用尚未确定。我们回顾性研究了26例因COPD导致高碳酸血症性通气衰竭的连续患者,这些患者吸氧治疗导致高碳酸血症恶化(定义为日间动脉二氧化碳分压(Pa,CO2)升至>8.0 kPa或夜间经皮二氧化碳分压(Ptc,CO2)升至>9 kPa)。所有患者均在夜间和白天午睡时接受面罩通气治疗(15例使用鼻面罩,11例使用全面罩)。15例患者需要额外的吸氧治疗。年平均死亡率为10.8%,1年和3年生存率分别为92%和68%。1年后,日间Pa,CO2中位数下降了1.35 kPa,动脉血氧分压(Pa,O2)上升了2.4 kPa。在未使用额外吸氧的患者中,1年后夜间Sa,O2中位数上升了12%,Ptc,CO2下降了2.8 kPa。6个月和1年时,血细胞比容显著低于治疗前。在身体健康导致的角色限制领域的生活质量(使用SF-36问卷测量)在6个月时显著改善。在这个选定的、临床气流阻塞稳定但无法耐受吸氧治疗并接受无创面罩通气治疗的组中,生存率高于历史对照,与能够耐受吸氧治疗的患者相当。生存率低与一秒用力呼气量低、体重指数低和夜间经皮二氧化碳分压高有关。单独使用面罩间歇正压通气或面罩间歇正压通气加补充吸氧治疗的患者在生存率上没有差异。